|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
23
|
|
pubmed:dateCreated |
1999-12-17
|
|
pubmed:abstractText |
We have previously disclosed dihydropyridines such as 1a,b as selective alpha(1a) antagonists as a potential treatment for benign prostatic hyperplasia (BPH). The propensity of dihydropyridines toward an oxidation led us to find suitable replacements of the core unit. The accompanying papers describe the structure-activity relationship (SAR) of dihydropyrimidinones 2a,b as selective alpha(1a) antagonists. We report herein the SAR of dihydropyrimidines such as 4 and highlight the similarities and differences between the dihydropyrimidine and dihydropyrimidinone series of compounds.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0022-2623
|
|
pubmed:author |
pubmed-author:BrotenT PTP,
pubmed-author:ChangR SRS,
pubmed-author:DiazV PVP,
pubmed-author:ForrayCC,
pubmed-author:GluchowskiCC,
pubmed-author:KlingPP,
pubmed-author:LángJJ,
pubmed-author:LaheSS,
pubmed-author:MarzabadiM RMR,
pubmed-author:MiaoS WSW,
pubmed-author:NagarathnamDD,
pubmed-author:O'MalleySS,
pubmed-author:RansomRR,
pubmed-author:SumPP,
pubmed-author:TianDD,
pubmed-author:VyasK PKP,
pubmed-author:WetzelJ MJM,
pubmed-author:WongW CWC,
pubmed-author:ZhangFF,
pubmed-author:ZhangKK
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
18
|
|
pubmed:volume |
42
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4804-13
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:10579843-Administration, Oral,
pubmed-meshheading:10579843-Adrenergic alpha-1 Receptor Antagonists,
pubmed-meshheading:10579843-Adrenergic alpha-Antagonists,
pubmed-meshheading:10579843-Animals,
pubmed-meshheading:10579843-Binding, Competitive,
pubmed-meshheading:10579843-Biological Availability,
pubmed-meshheading:10579843-Dogs,
pubmed-meshheading:10579843-Drug Design,
pubmed-meshheading:10579843-Drug Evaluation, Preclinical,
pubmed-meshheading:10579843-Humans,
pubmed-meshheading:10579843-Male,
pubmed-meshheading:10579843-Prostate,
pubmed-meshheading:10579843-Pyrimidines,
pubmed-meshheading:10579843-Rats,
pubmed-meshheading:10579843-Receptors, Adrenergic, alpha-1,
pubmed-meshheading:10579843-Recombinant Proteins,
pubmed-meshheading:10579843-Stereoisomerism,
pubmed-meshheading:10579843-Structure-Activity Relationship
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 4. Structure-activity relationship in the dihydropyrimidine series.
|
|
pubmed:affiliation |
Departments of Chemistry and Pharmacology, Synaptic Pharmaceutical Corporation, Paramus, NJ 07652, USA.
|
|
pubmed:publicationType |
Journal Article,
In Vitro
|
